Full Press Release Details
InMed Pharmaceuticals Announces Favorable Behavioral
Outcomes with INM-901
in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data
July 30, 2024 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a pharmaceutical company
focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today
announced positive results from initial data sets from a long-term (7 months of dosing) in vivo preclinical Alzheimer's Disease
("AD") study of INM-901 which confirms previously reported findings from a short-term (3 months of dosing) pilot study, as
disclosed in the Company's prior press release dated April 4, 2024
Similar to the short-term
pilot study, this long-term dosing study was conducted using the 5xFAD amyloidosis model with extended dosing duration and increased sample
size as compared to the short-term study. This long-term study had four groupings:
It is important to note
that disease severity increases with advancing age in this preclinical amyloidosis model such that groups in the long-term study had more
advanced AD than those in the previous short-term pilot study.
The study included an
assessment of several behavioral criteria across the four study groupings:
All assessments of the
INM-901-treated AD groups showed a positive trend towards behaviour similar to the untreated disease-free group, with most assessments
demonstrating a clear dose response. Furthermore, INM-901-treated AD groups achieved a statistically significant improvement in certain
behavior criteria in comparison to the placebo-treated AD groups. These results not only supported but in several instances improved upon
the prior short-term pilot study outcomes.
Dr. Eric Hsu, InMed's
Senior Vice President of Preclinical Research and Development, stated; "We are highly encouraged by the initial data sets from this
long-term dosing study, which support the previously observed improvements in behavioral outcomes seen in our initial short-term preclinical
Alzheimer's proof-of-concept study. INM-901 continues to demonstrate potential by targeting multiple biological pathways linked
to Alzheimer's Disease and may have potential to address the critical need for effective treatments."
The Company is conducting
further molecular analyses to better define the mechanisms of action and potential role of INM-901 in AD treatment. The analyses will
focus on the following areas using mRNA, protein and histological measurements:
Additionally, the development of the chemistry,
manufacturing, and controls (CMC) for both the drug substance and the drug product formulation is ongoing, with GLP studies in the planning
stages to support an IND submission.
Research and development
activities to date have demonstrated the potential of INM-901 to target several biological pathways associated with AD, including positive
pharmacological characteristics such as:
InMed Pharmaceuticals
is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors.
InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of rare cannabinoids
and proprietary small molecule drug candidates. For more information, visit www.inmedpharma.com.
Vice President, Investor
and Corporate Communications
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning
of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects",
"anticipates", "believes", "intends", "potential", "possible", "would"
and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks,
uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's
current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release
includes, but is not limited to, statements about: the efficacy of INM-901, INM-901's ability to treat AD, marketability and uses
for INM-901, the results of further studies into INM-901 and acceleration of the development of InMed's AD program as well as potential
GLP studies or IND submissions.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks
and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings
with the Securities and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified
in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results,
events or developments, except as required by law.